What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Robert M. Sharkey spends much of his time researching Radioimmunotherapy, Pretargeting, Pathology, Cancer and Antibody.
His Radioimmunotherapy research is included under the broader classification of Monoclonal antibody.
Robert M. Sharkey combines subjects such as Cancer research, Peptide, Hapten, Pretargeted Radioimmunotherapy and Transplantation with his study of Pretargeting.
He has included themes like Gastroenterology, Carcinoembryonic antigen, Metastasis and Colorectal cancer in his Pathology study.
The concepts of his Antibody study are interwoven with issues in Pancreatic cancer, Pharmacology, Antigen and Immunotherapy.
Robert M. Sharkey works mostly in the field of Internal medicine, limiting it down to topics relating to Oncology and, in certain cases, Refractory.
His most cited work include:
- Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy (303 citations)
- A Novel Method of 18F Radiolabeling for PET (270 citations)
- Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting (228 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Radioimmunotherapy, Antibody, Cancer research, Internal medicine and Monoclonal antibody.
The Radioimmunotherapy study combines topics in areas such as Nuclear medicine, Radiation therapy and Toxicity.
His Antibody study combines topics from a wide range of disciplines, such as Molecular biology, Biodistribution, Antigen and Pathology.
His Pathology study incorporates themes from Carcinoembryonic antigen and Metastasis.
His biological study deals with issues like Pancreatic cancer, which deal with fields such as Gemcitabine.
His studies deal with areas such as Gastroenterology and Oncology as well as Internal medicine.
He most often published in these fields:
- Radioimmunotherapy (34.01%)
- Antibody (31.70%)
- Cancer research (28.24%)
What were the highlights of his more recent work (between 2012-2021)?
- Internal medicine (27.67%)
- Sacituzumab govitecan (12.10%)
- Cancer (23.05%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Sacituzumab govitecan, Cancer, Irinotecan and Antibody-drug conjugate are his primary areas of study.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Oncology.
His studies in Sacituzumab govitecan integrate themes in fields like Camptothecin, Cancer research, Clinical trial and Antigen.
In his study, which falls under the umbrella issue of Cancer research, Molecular biology and Medullary thyroid cancer is strongly linked to Antibody.
In Antibody-drug conjugate, Robert M. Sharkey works on issues like SN-38, which are connected to Pharmacology.
His Pretargeting study is related to the wider topic of Radioimmunotherapy.
Between 2012 and 2021, his most popular works were:
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. (157 citations)
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) (133 citations)
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. (125 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
